HHHikaru Hashitani

Hikaru Hashitani

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Hikaru Hashitani has a total of 94 co-authors. Here are the top co-authors by number of shared publications:

  • Retsu Mitsui

    Department of Cell Physiology, Graduate School of Medical Sciences Nagoya City University Nagoya Japan

    14 shared publications
  • Hikaru Suzuki

    Department of Cell Physiology, Nagoya City University Graduate School of Medical Sciences, Nagoya and Department of Health Science and Social Welfare, Faculty of Human Sciences, Waseda University (RM), Tokorozawa, Japan

    9 shared publications
  • Retsu Mitsui

    Department of Cell Physiology, Graduate School of Medical Sciences, Nagoya City University, Nagoya, Japan

    7 shared publications
  • Christopher Henry Fry

    School of Physiology, Pharmacology & Neuroscience University of Bristol Bristol UK

    6 shared publications
  • Basu Chakrabarty

    School of Physiology, Pharmacology & Neuroscience University of Bristol Bristol UK

    4 shared publications
  • Kyoko Miwa‐Nishimura

    Department of Cell Physiology, Graduate School of Medical Sciences Nagoya City University Nagoya Japan

    4 shared publications

Latest Publications

  • Open Access

    Calcium‐activated chloride channels in smooth muscle organs: The ANO1 and only……?

    by Bernard T. Drumm, Paolo Tammaro, Hikaru Hashitani

  • Open Access

    Parasympathetic overdrive as a cause of overactive bladder in a high‐fat‐diet‐induced obesity mouse model

    by Ayu Sugiura, Retsu Mitsui, Kyoko Miwa‐Nishimura, Hikaru Hashitani

    Overactive bladder (OAB) is a highly prevalent condition characterized by urinary urgency that negatively affects quality of life. Because obesity and metabolic syndrome (MetS) are known as major risk factors for OAB, we explored the mechanisms underlying obesity‐/MetS‐associated OAB using a high‐fat‐diet (HFD)‐induced obesity mouse model. Four‐week‐old male C57BL6 mice were subjected to either a HFD (60 kcal% fat) or a normal diet (ND, 10 kcal% fat). Cystometry and bladder afferent activity recordings in anaesthetized mice, isometric tension recordings in detrusor smooth muscle (DSM) strips and intravesical pressure recordings in isolated whole bladders were performed after 12 weeks of ND or HFD feeding. Bladder morphology was examined using histochemistry. HFD mice exhibited a MetS phenotype characterized by abdominal obesity, hyperglycaemia and insulin resistance. HFD mice developed enlarged non‐voiding contractions (NVCs) during bladder filling associated with enhanced afferent activity. Both were attenuated by intravenous administration of atropine (1 mg/kg) or pyridoxalphosphate‐6‐azophenyl‐2′,4′‐disulfonic acid (PPADS), a P2X purinoceptor antagonist (10 mg/kg), or by bilateral pelvic nerve transection. In ND mice these drugs attenuated NVCs but not afferent activity. Spontaneous or nerve‐evoked DSM contractions or transient pressure increases in isolated whole bladders were unaltered in HFD mice. DSM thickness, collagen deposition or parasympathetic nerve density in HFD bladders was unaltered. Thus the OAB phenotype in HFD mice appears to primarily results from the increased parasympathetic neural activity during the bladder storage phase. These results provide the basis of the clinical effectiveness of anti‐muscarinic agents on OAB as well as the enhanced purinergic transmission in OAB patients known as ‘atropine resistance’. image Key points: High‐fat‐diet (HFD)‐induced obese mice exhibiting metabolic syndrome phenotype display overactive bladder (OAB) phenotype characterized by enlarged non‐voiding contractions (NVCs) associated with bladder afferent overactivity. Both enlarged NVCs and afferent overactivity in HFD mice are reversed by intravenous administration of atropine or the P2X receptor antagonist pyridoxalphosphate‐6‐azophenyl‐2′,4′‐disulfonic acid (PPADS), or by bilateral pelvic nerve transection. Detrusor muscle strip contractility, corresponding spontaneous pressure increases in isolated whole bladder and bladder morphology are unaltered in HFD mice. The OAB phenotype in HFD‐induced obese mice primarily results from excessive parasympathetic activity during the bladder storage phase. These findings provide a basis for the clinical effectiveness of anti‐muscarinic drugs on bladder storage symptoms as well as the relevance of enhanced purinergic transmission in OAB patients known as ‘atropine resistance’.

  • Open Access

    Calcium‐activated chloride channels in pericytes and their role in regulating organ blood flow

    by Paolo Tammaro, Hikaru Hashitani

    Pericytes are mural cells of the microvasculature, characterised by a distinctive ‘bump‐on‐a‐log’ morphology and elongated processes extending along the abluminal surface of capillary and pre‐ and post‐capillary segments. They are widely distributed across organs and exhibit functional heterogeneity. Contractile pericytes directly regulate local blood flow, whereas non‐contractile pericytes contribute to electrical signalling by generating depolarising or hyperpolarising events that propagate to upstream vessels and coordinate tissue perfusion. These functions are closely linked to intracellular ion homeostasis. Recent evidence highlights a role for Ca 2+ ‐activated Cl − channels (CaCCs), particularly TMEM16A (ANO1), in coupling intracellular Ca 2 + signals to membrane depolarisation and pericyte activity. In contractile pericytes, TMEM16A‐mediated currents promote depolarisation to activate L‐type voltage‐gated Ca 2 + channels, facilitating Ca 2+ entry to support contraction. In non‐contractile capillary pericytes, periodically generated TMEM16A‐dependent depolarisations contribute to the initiation and propagation of spontaneous electrical activity, supporting intercellular synchrony within microvascular networks. Alternatively, asynchronous TMEM16A‐dependent depolarisations could sum with each other to maintain resting membrane potentials and basal vascular tone. In this review, we summarise current understanding of CaCC channel function in pericytes across organs, and discuss emerging directions for future research and therapeutic targeting. image


  • Open Access

    Inhibitory effects of somatostatin on glucagon-like peptide-1-mediated acceleration of peristalsis in the rat proximal colon

    by Hiroyuki Nakamori, Fuko Hosoi, Hikaru Hashitani

    Somatostatin inhibited the prokinetic action of glucagon-like peptide-1 (GLP-1), short-chain fatty acids, and lipopolysaccharide. The inhibitory effect of somatostatin was mediated by the activation of somatostatin receptor subtype 5 that was expressed on L cells. Sources of somatostatin were D cells and intrinsic primary afferent neurons, both of which expressed GLP-1 receptors. Thus, colonic peristalsis may well be regulated by the functional interaction between excitatory GLP-1 and inhibitory somatostatin.

  • Open Access

    Intramural Blood Vessels as a Primary Site of Vascular LUTS

    by Hikaru Hashitani, Retsu Mitsui

    Ischaemia has been considered a primary cause of lower urinary tract symptoms (LUTS). The existing concept is that ischaemic LUTS develops subsequent to structural narrowing of feeder arteries of the LUT due to atherosclerosis. However, the distribution of blood flow within each LUT organ that is regulated by intramural microvasculature should also be considered. Thus, the blood supply of the mucosal and detrusor smooth muscle (DSM) in the bladder and the blood flow of the mucosal, smooth muscle and striated muscle in the urethra need to be adjusted to meet their differing energy consumption. Sympathetic overdrive that is commonly seen in aged populations and patients with metabolic syndrome enhances arteriolar constrictions resulting in a disturbed intramural flow distribution so that cell populations with a higher energy demand are more readily affected. In addition to endothelial nitric oxide (NO) that plays a pivotal role in regulating vasocontractility, NO released from perivascular parasympathetic nerves appears to counteract sympathetic activity (sympatholysis) in the LUT. Thus, any diminished neuronally released NO would cause sympathetic overactivity. Capillary rarefaction, the reduced density/function of capillaries, the site of blood‐tissue exchange, would also be critically involved in the pathogenesis of LUTS. In the bladder, capillary pericytes appear to function as pacemaker cells driving arteriolar vasomotion facilitating capillary perfusion and may also play a role in maintaining suburothelial homeostasis. Considering the fundamental roles of the intramural microvasculature in maintaining LUT functions, enhanced NO‐mediated sympatholysis and/or capillary revascularization could have therapeutic and preventive potential for the ischaemic LUT.

  • Role of ANO1 Ca2+-activated Cl− channels in the generation of propagating spontaneous Ca2+ transients of mouse bladder suburothelial pericytes

    by Ayu Sugiura, Retsu Mitsui, Kyoko Miwa-Nishimura, Hikaru Hashitani

    Pericytes in microvasculature of the bladder suburothelium develop spontaneous Ca2+ transients that propagate within the pericyte network. Here, the expression of ANO1 Ca2+-activated Cl- channels that serve as smooth muscle pacemaker channels was investigated in mural cells of the mouse bladder microvasculature. The involvement of ANO1 in the generation of propagating spontaneous Ca2+ transients or vasocontractions was also examined. Fluorescence immunohistochemistry was utilised to visualise ANO1 expression in different microvascular segments. Intercellular Ca2+ dynamics in pericytes of capillaries or pre-capillary arterioles (PCAs) were visualised using NG2-GCaMP6 mice, while Ca2+ signals in venular pericytes were detected using Cal-520 fluorescence. Spontaneous or electrical field stimulation (EFS)-induced vascular diameter changes were measured using a video-tracking system. ANO1 expression was greatest in capillary pericytes, followed by pericytes in PCAs or post-capillary venules, while arteriolar smooth muscle cells (SMCs) or venular pericytes exhibited lower ANO1 immunoreactivity. In capillaries where pericytes developed nifedipine-resistant propagating spontaneous Ca2+ transients, Ani9 (3 µM), the specific ANO1 inhibitor, disrupted the intercellular synchrony of Ca2+ transients. In venules, Ani9 disrupted the synchrony of spontaneous Ca2+ transients amongst venular pericytes and prevented the generation of spontaneous phasic constrictions (SPCs). Ani9 also diminished EFS-evoked, α-adrenergic venular constrictions. In contrast, Ani9 failed to attenuate EFS-induced, predominantly α-adrenergic constrictions in arterioles where SPCs were absent. Thus, ANO1 appears to play a fundamental role in the generation of propagating spontaneous Ca2+ transients in capillary, PCA and venular pericytes. Lack of spontaneous Ca2+ transients/SPCs in arterioles may be partly attributable to the low ANO1 expression in arteriolar SMCs.


  • Open Access

    The Lower Urinary Tract Science Group Abstracts—ICI‐RS 2024

    by Christopher H. Fry, Andrew Gammie, Bahareh Vahabi, Faezeh A. Hassani, Karen D. McCloskey, Mathijs M. de Rijk, Pradeep Tyagi, Hikaru Hashitani, Michael Winder, Patrik Aronsson, et al.


  • Think Tank 2: How Do We Precisely Define the “High Risk Bladder” and What Are the Interrelationships Between Inflammation, Blood Flow, Fibrosis, and Loss of Bladder Compliance?

    by Salvador Arlandis, Christopher Fry, Michel Wyndaele, Apostolos Apostolidis, Enrico Finazzi‐Agró, Pradeep Tyagi, Michael Winder, Hikaru Hashitani, Giovanni Mosiello, Marcio Augusto Averbeck, et al.

    Introduction: Defining “high‐risk bladder” or “high‐pressure bladder” involves recognizing the potential for an unsafe lower urinary tract, where dysfunction in storage and micturition can threaten upper urinary tract health, leading to unfavorable outcomes like dialysis, recurrent infections, systemic impact, or mortality.Methods: ICI‐RS was held in Bristol in June 2024, and Think Tank 2 aimed to define research priorities including identifying clinical predictors and developing prevention and monitoring strategies.Results: Risk factors encompass both congenital and neurogenic lower urinary tract dysfunction, bladder outlet obstruction, vascular diseases, and inflammatory disorders, but a validated stratification risk is lacking. Reduced compliance and detrusor overactivity lead to high filling pressures and raised detrusor leak point pressure, playing urodynamic studies a crucial role in risk assessment, though further research is needed for different neurogenic populations. Congenital conditions such as spina bifida, posterior urethral valves, and bladder exstrophy also contribute to a high‐risk bladder through fibrosis and reduced compliance. Inflammation and ischemia are key factors, with inflammation leading to fibrosis and impaired bladder storage and voiding function. Novel treatments, including sGC activators, PDE5 inhibitors, and regenerative therapies like stem cell injections and extracorporeal shock wave treatment, show promise in mitigating fibrosis and improving bladder compliance.Conclusions: Identifying and validating clinical risk stratification models, precise biomarkers and therapeutic windows remains essential for effective management and reversal of bladder fibrosis and dysfunction.


  • Lipopolysaccharide accelerates peristalsis by stimulating glucagon‐like peptide‐1 release from L cells in the rat proximal colon

    by Hiroyuki Nakamori, Atsuko Niimi, Retsu Mitsui, Hikaru Hashitani

    Upon epithelial barrier dysfunction, lipopolysaccharide (LPS) stimulates glucagon‐like peptide‐1 (GLP‐1) secretion from enteroendocrine L cells by activating Toll‐like receptor 4 (TLR4). Because GLP‐1 accelerates peristalsis in the proximal colon, the present study aimed to explore whether LPS facilitates colonic peristalsis by stimulating L cell‐derived GLP‐1 release. In isolated segments of rat proximal colon that were serosally perfused with physiological salt solution and luminally perfused with 0.9% saline, peristaltic wall motion was video recorded and converted into spatio‐temporal maps. Fluorescence immunohistochemistry was also carried out. Intraluminal administration of LPS (100 or 1 µg mL−1 but not 100 ng mL−1) increased the frequency of oro‐aboral propagating peristaltic contractions. The LPS‐induced acceleration of colonic peristalsis was blocked by TAK‐242 (the TLR4 antagonist), exendin‐3 (the GLP‐1 receptor antagonist) or BIBN4096 (the calcitonin gene‐related peptide receptor antagonist). GLP‐1‐positive epithelial cells co‐expressed TLR4 immunoreactivity. In aspirin‐pretreated preparations where epithelial barrier function had been impaired, a lower dose of LPS (100 ng mL−1) became capable of accelerating peristalsis. By contrast, luminally applied dimethyl sulphoxide, a reactive oxygen species scavenger that protects epithelial integrity, attenuated the prokinetic effects of a higher dose of LPS (100 µg mL−1). In colonic segments of a stress rat model leading to a leaky gut, LPS induced more pronounced prokinetic effects. Colonic L cells may well sense luminal LPS via TLR4 triggering the release of GLP‐1 that stimulates calcitonin gene‐related peptide‐containing neurons. The resultant acceleration of peristalsis would facilitate excretion of Gram‐negative bacteria from the intestine, and thus L cells may have a protective role against intestinal bacterial infections. image Key points: Colonic epithelial cells form a barrier against bacterial invasion but also may contribute more actively to the exclusion of luminal pathogen by stimulating colonic motility. Luminal lipopolysaccharide (LPS) accelerated colonic peristalsis by stimulating calcitonin gene‐related peptide‐containing neurons. The prokinetic effect of LPS was mediated by the secretion of glucagon‐like peptide‐1 from enteroendocrine L cells in which Toll‐like receptor 4 was expressed. The LPS‐mediated acceleration of peristalsis depended on epithelial barrier integrity. L cells have a defensive role against Gram‐negative bacterial infections by facilitating faecal excretion, and could be a potential therapeutic target for gastrointestinal infections.


  • Stress-induced impairment of parasympathetic NO-mediated inhibition of sympathetic vasoconstriction in submucosal arteriole of rat rectum

    by Retsu Mitsui, Mizuki Yamori, Hiroyuki Nakamori, Hikaru Hashitani

    In the gastrointestinal tract, nitrergic inhibition of the arteriolar contractility has not been demonstrated. Here, we explored whether neurally-released nitric oxide (NO) inhibits sympathetic vasoconstrictions in the rat rectal arterioles. Changes in sympathetic vasoconstrictions and their nitrergic modulation in rats exposed to water avoidance stress (WAS, 10 days, 1 h per day) were also examined. In rectal submucosal preparations, changes in arteriolar diameter were monitored using video microscopy. In control or sham-treated rats, electrical field stimulation (EFS)-induced sympathetic vasoconstrictions were increased by the neuronal nitric oxide synthase (nNOS) inhibitor L-NPA (1 μM) and diminished by the cyclic guanosine monophosphate-specific phosphodiesterase 5 (PDE5) inhibitor tadalafil (10 nM). In phenylephrine-constricted, guanethidine-treated arterioles, EFS-induced vasodilatations were inhibited by the calcitonin gene-related peptide (CGRP) receptor antagonist BIBN-4096 (1 μM) but not L-NPA. Perivascular nNOS-immunoreactive nitrergic fibres co-expressing the parasympathetic marker vesicular acetylcholine transporter (VAChT) were intermingled with tyrosine hydroxylase (TH)-immunoreactive sympathetic fibres expressing soluble guanylate cyclase (sGC), a receptor for NO. In WAS rats in which augmented sympathetic vasoconstrictions were developed, L-NPA failed to further increase the vasoconstrictions, while tadalafil-induced inhibition of the vasoconstrictions was attenuated. Phenylephrine- or α,β-methylene ATP-induced vasoconstrictions and acetylcholine-induced vasodilatations were unaltered by WAS. Thus, in arterioles of the rat rectal submucosa, NO released from parasympathetic nerves appears to inhibit sympathetic vasoconstrictions presumably by reducing sympathetic transmitter release. In WAS rats, sympathetic vasoconstrictions are augmented at least partly due to the diminished pre-junctional nitrergic inhibition of transmitter release without changing α-adrenoceptor or P2X-purinoctor mediated vasoconstriction and endothelium-dependent vasodilatation.